Disc Medicine, Inc./$IRON
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Disc Medicine, Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Ticker
$IRON
Sector
Primary listing
Employees
125
Headquarters
Website
IRON Metrics
BasicAdvanced
$2.9B
-
-$4.53
2.50
-
Price and volume
Market cap
$2.9B
Beta
2.5
52-week high
$95.95
52-week low
$30.82
Average daily volume
536K
Financial strength
Current ratio
32.107
Quick ratio
31.543
Long term debt to equity
4.932
Total debt to equity
5.035
Interest coverage (TTM)
-70.94%
Profitability
EBITDA (TTM)
-168.637
Effective tax rate (TTM)
-0.32%
Management effectiveness
Return on assets (TTM)
-17.95%
Return on equity (TTM)
-26.36%
Valuation
Price to book
4.73
Price to tangible book (TTM)
4.73
Price to free cash flow (TTM)
-19.806
Free cash flow yield (TTM)
-5.05%
Free cash flow per share (TTM)
-4.225
Growth
Earnings per share change (TTM)
23.59%
3-year earnings per share growth (CAGR)
1.90%
Bulls say / Bears say
Disc Medicine secured positive feedback from the FDA in a July 21 2025 pre-NDA meeting, confirming alignment on key CMC and endpoint parameters and keeping the planned October 2025 NDA submission for bitopertin on track (FT.com).
The company completed a $259 million public offering in January 2025, bolstering its balance sheet and extending its cash runway into at least 2028 (GlobeNewswire).
Disc Medicine is advancing its pipeline beyond EPP, with the Phase 2 DISC-3405 trial in polycythemia vera set to initiate in H1 2025, reflecting diversification of clinical assets (GlobeNewswire).
Net loss widened to $34.1 million in Q1 2025 from $26.9 million in Q1 2024, indicating increased cash burn as the company invests in its pipeline (GlobeNewswire).
Research and development expenses climbed to $27.8 million in Q1 2025 from $23.7 million year-over-year, highlighting rising costs that could pressure future cash flows if trials extend beyond projections (GlobeNewswire).
Selling, general and administrative expenses jumped to $12.2 million in Q1 2025 from $7.8 million, suggesting growing overhead ahead of potential product commercialization without near-term revenue to offset these costs (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Disc Medicine, Inc. stock?
Disc Medicine, Inc. (IRON) has a market cap of $2.9B as of October 25, 2025.
What is the P/E ratio for Disc Medicine, Inc. stock?
The price to earnings (P/E) ratio for Disc Medicine, Inc. (IRON) stock is 0 as of October 25, 2025.
Does Disc Medicine, Inc. stock pay dividends?
No, Disc Medicine, Inc. (IRON) stock does not pay dividends to its shareholders as of October 25, 2025.
When is the next Disc Medicine, Inc. dividend payment date?
Disc Medicine, Inc. (IRON) stock does not pay dividends to its shareholders.
What is the beta indicator for Disc Medicine, Inc.?
Disc Medicine, Inc. (IRON) has a beta rating of 2.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.